These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25781030)

  • 1. Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.
    Kalaska B; Kaminski K; Sokolowska E; Czaplicki D; Kujdowicz M; Stalinska K; Bereta J; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
    PLoS One; 2015; 10(3):e0119486. PubMed ID: 25781030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin.
    Sokolowska E; Kalaska B; Kaminski K; Lewandowska A; Blazejczyk A; Wietrzyk J; Kasacka I; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
    Front Pharmacol; 2016; 7():60. PubMed ID: 27014072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.
    Kalaska B; Sokolowska E; Kaminski K; Szczubialka K; Kramkowski K; Mogielnicki A; Nowakowska M; Buczko W
    Eur J Pharmacol; 2012 Jul; 686(1-3):81-9. PubMed ID: 22579410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote.
    La CC; Smith SA; Kalathottukaren MT; Haynes CA; Morrissey JH; Kizhakkedathu JN
    Adv Healthc Mater; 2024 Aug; 13(20):e2400108. PubMed ID: 38537246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New synthetic peptide with efficacy for heparin reversal and low toxicity and immunogenicity in comparison to protamine sulfate.
    Li T; Meng Z; Zhu X; Gan H; Gu R; Wu Z; Li J; Zheng Y; Liu T; Han P; Han S; Dou G
    Biochem Biophys Res Commun; 2015 Nov; 467(3):497-502. PubMed ID: 26456655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The toxicology of heparin reversal with protamine: past, present and future.
    Sokolowska E; Kalaska B; Miklosz J; Mogielnicki A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):897-909. PubMed ID: 27223896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists.
    Kamiński K; Płonka M; Ciejka J; Szczubiałka K; Nowakowska M; Lorkowska B; Korbut R; Lach R
    J Med Chem; 2011 Oct; 54(19):6586-96. PubMed ID: 21866887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.
    Fazavana J; Bianchini EP; Saller F; Smadja C; Picard V; Taverna M; Borgel D
    J Thromb Haemost; 2013 Jun; 11(6):1128-36. PubMed ID: 23581397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
    Kalaska B; Kaminski K; Miklosz J; Yusa SI; Sokolowska E; Blazejczyk A; Wietrzyk J; Kasacka I; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
    Transl Res; 2016 Nov; 177():98-112.e10. PubMed ID: 27456749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caltrop-like Small-Molecule Antidotes That Neutralize Unfractionated Heparin and Low-Molecular-Weight Heparin In Vivo.
    Zong Y; Lei Z; Yu SB; Zhang LY; Wu Y; Feng K; Qi QY; Liu Y; Zhu Y; Guo P; Zhou W; Zhang DW; Li ZT
    J Med Chem; 2024 Mar; 67(5):3860-3873. PubMed ID: 38407934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.
    Bianchini EP; Fazavana J; Picard V; Borgel D
    Blood; 2011 Feb; 117(6):2054-60. PubMed ID: 21048158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porous Polymers as Universal Reversal Agents for Heparin Anticoagulants through an Inclusion-Sequestration Mechanism.
    Lin F; Yu SB; Liu YY; Liu CZ; Lu S; Cao J; Qi QY; Zhou W; Li X; Liu Y; Tian J; Li ZT
    Adv Mater; 2022 Jun; 34(23):e2200549. PubMed ID: 35499202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
    Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
    AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.
    Kalathottukaren MT; Abraham L; Kapopara PR; Lai BF; Shenoi RA; Rosell FI; Conway EM; Pryzdial EL; Morrissey JH; Haynes CA; Kizhakkedathu JN
    Blood; 2017 Mar; 129(10):1368-1379. PubMed ID: 28034889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine.
    Bianchini EP; Sebestyen A; Abache T; Bourti Y; Fontayne A; Richard V; Tamion F; Plantier JL; Doguet F; Borgel D
    Br J Haematol; 2018 Mar; 180(5):715-720. PubMed ID: 29363751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents.
    Miklosz J; Kalaska B; Kaminski K; Rusak M; Szczubialka K; Nowakowska M; Pawlak D; Mogielnicki A
    Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31533230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin.
    Li T; Meng Z; Zhu X; Gan H; Gu R; Wu Z; Liu T; Han P; Gao J; Han S; Dou G
    FEBS Open Bio; 2021 Sep; 11(9):2468-2489. PubMed ID: 34184429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4.
    Sasaki E; Minamiguchi K; Kitazato KT; Nagase H; Kitazato K
    Haemostasis; 1997; 27(4):174-83. PubMed ID: 9483172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.